Fig. 1
Targeting FAK in combination with anthracyclines exhibits the most potent cancer cell killing through chemotherapeutic drug screening. A Patient ratios of copy number amplification across different cancer types from TCGA datasets. B-C The correlation analysis between log2 copy numbers and mRNA levels of PTK2 or FAK protein levels in ovarian cancer from TCGA datasets. R.2 and slope non-zero p value were obtained to analyze correlation significance. D-E The overall and progression-free survival analyses between patients with PTK2 high amplification (copy number > 7) and without PTK2 copy number variation for ovarian cancer from TCGA datasets. F-G The cell-killing effects of IN10018 or defactinib in the treatment of different ovarian cancer cell lines (n = 3 per point). H The antitumor effects of IN10018 in the treatment of different ovarian cancer animal models including 6 CDX models and 3 PDX models (n = 3 per group). I The drug details of the chemotherapeutic drug screening. J-K The IC50 comparison between the tested drugs alone (x-axis) or the combination of tested drugs and 3 μM IN10018 (y-axis) in the screening with ovarian cancer cell lines A2780 or SK-OV-3. Data represent mean ± SEM. Log-rank testing was performed for the analysis of statistical significance. The unpaired student's T-test was used for the other statistical analysis. NS means non-significant, *P < 0.05, and **P < 0.01